Darbepoetin alfa therapeutic interchange protocol for anemia in dialysis

Annals of Pharmacotherapy

Volumn 39, Issue 11, 2005, Pages 1808-1811

  Brophy, Donald F ^a   Ripley, Elizabeth B D ^a   Kockler, Denise R ^b   Lee, Seina ^a   Proeschel, Lori A ^b,c  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VCU Health System   (United States)

^c Sentara Health Systems   (United States)

Author keywords

Darbepoetin alfa; Dialysis; Erythropoietin alfa; anemia

Indexed keywords

ERYTHROPOIETIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL PROTOCOL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIALYSIS; DRUG COST; DRUG DOSE REGIMEN; DRUG SUBSTITUTION; DRUG USE; EVALUATION; FEMALE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MONEY; PRIORITY JOURNAL; QUALITY OF LIFE; SCREENING; UNITED STATES;

ANEMIA; CHRONIC DISEASE; CLINICAL PROTOCOLS; COSTS AND COST ANALYSIS; DRUG ADMINISTRATION SCHEDULE; DRUG UTILIZATION REVIEW; EPOETIN ALFA; ERYTHROPOIETIN; FEMALE; HEMOGLOBINS; HOSPITALS, UNIVERSITY; HUMANS; INJECTIONS, INTRAVENOUS; KIDNEY DISEASES; LENGTH OF STAY; MALE; MIDDLE AGED; RENAL DIALYSIS; THERAPEUTIC EQUIVALENCY; VIRGINIA;

EID: 27344439248     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G329     Document Type: Article

References (8)

1. National Kidney Foundation, Kidney Disease Outcomes Quality Initiative (K/DOQI) clinical practice guidelines for the treatment of anemia of chronic renal failure. www.kidney.org/professionals/kdoqi/guidelines_updates/doqi_uptoc. html#an (accessed 2004 Dec 13).
2. Brophy DF, Ripley EBD, Holdford DA. Pharmacoeconomic considerations in the health system management of anaemia in patients with chronic kidney disease and end stage renal disease. Expert Opin Pharmacother 2003;4:1461-9.
3. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 1996;28:53-61.
4. Santoro A. Anemia in renal insufficiency. Rev Clin Exp Hematol 2002;(suppl 1):12-20.
5. Leese B, Hutton J, Maynard A. A comparison of the costs and benefits of recombinant human erythropoietin (epoetin) in the treatment of chronic renal failure in 5 European countries. Pharmacoeconomics 1992;1:346-56.
6. McNamee P, Van Doorslaer E, Segaar R. Benefits and costs of recombinant human erythropoietin for end-stage renal disease. Int J Technol Assess Health Care 1993;9:490-504.
7. Package insert. Aranesp (darbepoetin alfa). Thousand Oaks, CA: Amgen, December 2003.
8. Anderson ER, Gibson G. Considerations in darbepoetin alfa cost and reimbursement: a model for pharmacy managers. Pharmacotherapy 2003;23(12 pt2):119S-24S.